| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2532727 | European Journal of Pharmacology | 2011 | 5 Pages |
Abstract
⺠In a validated animal model of pulmonary hypertension we tested chronic treatment with aminaftone, a novel inhibitor of endothelin-1 synthesis. ⺠Aminaftone increased survival, reduced right ventricular and right atrial hypertrophy. ⺠Aminaftone reduced plasma concentrations of endothelin-1 and medial wall thickness of pulmonary arteries. ⺠Aminaftone may represent a novel treatment for pulmonary hypertension, possibly in association with other drugs.
Related Topics
Life Sciences
Neuroscience
Cellular and Molecular Neuroscience
Authors
Vanessa Zambelli, Alessandro Santaniello, Francesca Fumagalli, Serge Masson, Raffaella Scorza, Lorenzo Beretta, Roberto Latini,